Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02412423

Enrollment

Registered

2015-04-09

Start date

2015-03-31

Completion date

2017-03-31

Last updated

2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplantation

Brief summary

In beijing model for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in beijing model.

Interventions

DRUGpost-transplantation cyclophosphamide

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* haploidentical patients from maternal or collateral donors

Exclusion criteria

* uncontrolled infection before transplant

Design outcomes

Primary

Measure	Time frame
rate of acute GVHD	participants will be followed for an expected average of 365 days

Secondary

Measure	Time frame
rate of non-relapse mortality	participants will be followed for an expected average of 365 days
rate of relapse	participants will be followed for an expected average of 365 days
probability of survival	participants will be followed for an expected average of 365 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026